Drug
PSMA-targeted Docetaxel Nanoparticles BIND-014 clinical trials
Also written BIND-014.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
BIND Therapeutics (5)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic Agents source
Studies
Open first, then newest update. How each study uses PSMA-targeted Docetaxel Nanoparticles BIND-014 is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung CancerCompletedPhase 2BIND TherapeuticsNCT02283320Written as BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
- A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate CancerCompletedPhase 2BIND TherapeuticsNCT01812746Written as BIND-014
- A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung CancerCompletedPhase 2BIND TherapeuticsNCT01792479Written as BIND-014
- A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and NeckTerminatedPhase 2BIND TherapeuticsNCT02479178Written as BIND-014 (docetaxel nanoparticles for injectable suspension)
- A Study of BIND-014 Given to Patients With Advanced or Metastatic CancerCompletedPhase 1BIND TherapeuticsNCT01300533Written as BIND-014